If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

Share Price is delayed by 15 minutes
Get Live Data
58.60    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.80 (4.895%)
Market Cap: £47.72m
FLO Live PriceLast checked at - London Stock Exchange

Intraday Flowtech Fluid. Share Chart

Delisting and Compulsory Acqu

29 Jul 2008 07:00

RNS Number : 0658A
Mentor Graphics Corporation
29 July 2008
Β 

ο»Ώ

Not for release, publication or distribution, in whole or in part, in, into or from theΒ United States,Β Canada,Β AustraliaΒ or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

FOR IMMEDIATE RELEASE

29Β JULYΒ 2008

REVISED,Β RECOMMENDEDΒ AND MANDATORYΒ CASHΒ OFFER FORΒ FLOMERICSΒ GROUP PLCΒ ("FLOMERICS" OR THE "COMPANY") BYΒ MENTOR GRAPHICS CORPORATIONΒ ("MENTOR")

Delisting

MentorΒ announces thatΒ it has attained in excess of 75 per cent. of the voting rights attaching to Flomerics Shares, andΒ has taken steps to procure theΒ application byΒ FlomericsΒ for theΒ cancellation of the listing of Flomerics Shares on AIM and the cancellation of trading in Flomerics Shares on AIM. It is anticipated that cancellation ofΒ listing and trading will take effect no earlier thanΒ 27Β August 2008.

This follows theΒ announcement on 10 July 2008Β byΒ MentorΒ that all of theΒ conditions of itsΒ RecommendedΒ Offer for the entire issued and to be issuedΒ ordinary share capital ofΒ FlomericsΒ have been satisfied or waived andΒ the Offer is now declared unconditional in all respects.

Following such delisting the liquidity and marketability of any Flomerics Shares that are not acquired byΒ MentorΒ would be significantly reduced. It isΒ Mentor's intention that, after such cancellation, Flomerics will be re-registered as a private company under the relevant provisions of the Companies Act 1985.Β 

Compulsory acquisition of outstandingΒ Flomerics Shares.

MentorΒ alsoΒ announces that by 3.00 pm onΒ 28Β July 2008 it had received valid acceptances in respect of or otherwise contracted to acquireΒ 21,378,423Β Flomerics Shares, representing approximatelyΒ 93.00Β per cent of the Flomerics Shares to which the Offer relates.

Accordingly,Β MentorΒ announces thatΒ compulsory acquisition notices under section 979 of the Companies ActΒ 2006 will be despatchedΒ to the holders of Flomerics Shares who have not yet accepted the Offer. The Offer will remain open for acceptance until further notice. Flomerics Shareholders who have not yet accepted the Offer are reminded to complete and return the Forms of Acceptance as soon as possible.

If you have any queries,Β please contactΒ Computershare onΒ 0870 707Β 1725 or,Β if callingΒ from outside theΒ UK, on +44 870 707Β 1725.

OtherΒ 

Terms defined in the Recommended Offer Document shall, unless the context otherwise requires, haveΒ the same meanings in this announcement.Β The term 'acting in concert' shall have the same meaning as in the City Code.

Enquiries:

Mentor Graphics Corporation
Β 
Ryerson Schwark
Tel: +1 503 685 7000
Β 
Β 
Cenkos Securities plc
Β 
Nicholas Wells
Tel: +44 20 7397 8900
Β 
Β 
Bell Pottinger Corporate & Financial
Β 
David Rydell
Β 
Olly Scott
Tel: +44 20 7861 3232
Β 
Β 
Flomerics Group plc
Β 
Gary Carter
Β 
Keith Butcher
Tel: +44 20 8487 3000
Β 
Β 
Jefferies International Limited
Β 
Andres Pieczanski
Β 
Sarah McNicholas
Tel: +44 20 7029 8000
Β 
Β 
Oriel Securities Limited
Β 
Andrew Edwards
Β 
Michael Shaw
Tel: +44 20 7710 7600
Β 
Β 
Citigate Dewe Rogerson
Β 
Ginny Pulbrook
Β 
Seb Hoyle
Tel: +44 20 7638 9571

Cenkos, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively forΒ MentorΒ andΒ no one else in connection with the Offer and will not be responsible to anyone other thanΒ MentorΒ for providing the protections afforded to its customers or for providing advice in relation to the Offer or in relation to the contents of this announcement or any transaction or arrangement referred to herein.

Canaccord,Β which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively forΒ MentorΒ andΒ no one else in connection with the Offer and will not be responsible to anyone other thanΒ MentorΒ for providing the protections afforded to its customers or for providing advice in relation to the Offer or in relation to the contents of this announcement or any transaction or arrangement referred to herein.

This announcement is not intended to and does not constitute, or form any part of, an offer or an invitation to purchase, subscribe for or otherwise acquire, sell or dispose ofΒ any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Offer or otherwise.Β Β The OfferΒ isΒ made solely through theΒ RecommendedΒ Offer Document and the Form of Acceptance, which together contain the full terms and conditions of the Offer, including details of how to accept the Offer.Β Β AnyΒ acceptance or other response to the Offer should be made only on the basis of the information contained in theΒ RecommendedΒ Offer Document and the Form of Acceptance.Β Β The laws of relevant jurisdictions may affect the availability of the Offer to persons not resident in theΒ United Kingdom.Β Β Persons who are not resident in theΒ United Kingdom, or who are subject to the laws of any jurisdiction other than theΒ United Kingdom, should inform themselves about and observe any applicable legal and regulatory requirements.Β Β TheΒ RecommendedΒ Offer DocumentΒ isΒ available for public inspectionΒ at the offices of Cenkos.Β 

The OfferΒ isΒ not beingΒ made, directly or indirectly, in or into the United States or by use of mails of, or any means or instrumentality (including, without limitation, facsimile transmission, telephoneΒ or internet) of inter-state or foreign commerce of, or any facilities ofΒ a national, stateΒ or other securities exchange ofΒ the United States, norΒ isΒ it beingΒ made directlyΒ or indirectly in or into CanadaΒ orΒ Australia and the OfferΒ isΒ not capable of acceptance by any such use, means, instrumentality orΒ facilitiesΒ or from within the United States, Canada orΒ Australia or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction.Β Β Accordingly, copies of this announcement are not being, will not be and must not be mailed or otherwise forwarded, distributed or sent in, into orΒ from the United States, Canada orΒ Australia or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction and persons receiving this announcement (including without limitation custodians, nominees and trustees) must not mail,Β or otherwiseΒ forward, distribute or send it in, into or from the United States, CanadaΒ orΒ Australia or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
CASDDGDRSGDGGII
Date   Source Headline
19th Jun 202612:52 pmRNS2026 Annual General Meeting - Result of voting
4th Jun 20267:00 amRNSAcquisition of Helipebs Controls Ltd
28th May 20267:00 amRNS2025 Annual Report Posting & Notice of AGM
8th May 20262:28 pmRNSHolding(s) in Company
7th Apr 20267:00 amRNSAnnual Financial Report
24th Mar 20267:00 amRNSAudited Preliminary FY25 Results & Outlook update
18th Mar 20267:00 amRNSNotice of Annual results and presentation
12th Feb 20264:22 pmRNSCompletion of Acquisition
10th Feb 20264:36 pmRNSHolding(s) in Company
9th Feb 20265:25 pmRNSHolding(s) in Company
9th Feb 20264:28 pmRNSDirector/PDMR Shareholding
6th Feb 202612:08 pmRNSResult of General Meeting
22nd Jan 20264:12 pmRNSHolding(s) in Company (Correction)
22nd Jan 20262:36 pmRNSResult of Retail Offer
22nd Jan 202612:56 pmRNSHolding(s) in Company
22nd Jan 202612:48 pmRNSHolding(s) in Company
21st Jan 20262:44 pmRNSPublication of Circular
20th Jan 20263:26 pmRNSResult of Placing and Notice of General Meeting
20th Jan 20267:02 amRNSProposed Retail Offer
20th Jan 20267:01 amRNSProposed Placing And Retail Offer
20th Jan 20267:00 amRNSFull Year Trading Update & Acquisition
1st Oct 202510:39 amRNSChange of Auditor
9th Sep 20257:00 amRNSHalf-Year Report - six months ended 30 June 2025
4th Sep 20258:00 amRNSHalf-Year results - webcast presentations
29th Jul 20257:00 amRNSGroup Trading Update & Notice of Interim Results
22nd Jul 20257:00 amRNS-RNew Contract wins & Partnerships
18th Jun 20258:00 amRNS-RFlowtech wins Waterside City bridge contract
17th Jun 20252:26 pmRNSResult of AGM
27th May 20255:13 pmRNSCorrection re: timing of the 2025 AGM on 17 June
22nd May 20257:00 amRNSAvailability - FY24 Annual Report & Notice of AGM
21st May 202510:30 amRNS-RFlowtech capitalises on acquisitions opportunities
11th Apr 20257:00 amRNSDirector/PDMR Shareholding
9th Apr 20257:00 amRNSPreliminary results - year ended 31 December 2024
4th Apr 20251:19 pmRNSNotice of Results and webcast presentations
12th Feb 202511:00 amRNSDirector/PDMR Shareholding
30th Jan 20257:00 amRNSFULL YEAR TRADING UPDATE
23rd Dec 20241:53 pmRNSHolding(s) in Company
30th Sep 20247:00 amRNSPDMR - Director share dealing
26th Sep 20247:00 amRNS2024 Half-year Report & Trading update
18th Sep 20247:00 amRNSAppt of Joint Broker & Notice of Half-year results
27th Aug 20247:00 amRNSAcquisition of Thomas Wright/Thorite Group Ltd
31st Jul 20247:00 amRNSHolding(s) in Company
30th Jul 20247:00 amRNSGroup Trading Update & Notice of Interim Results
1st Jul 20247:00 amRNSChange of Adviser
19th Jun 20245:46 pmRNSHolding(s) in Company
18th Jun 20245:42 pmRNSIssue of shares to the Employees Benefit Trust
11th Jun 202412:17 pmRNSResult of AGM
31st May 202412:19 pmRNSHolding(s) in Company
22nd May 20246:03 pmRNSHolding(s) in Company
22nd May 20247:00 amRNSExercise of Warrant, Issue of new shares & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.